Table 3.

Lipid and hormone plasma levels in MI-resistant patients at baseline and after MI plus α-LA treatment

Plasma levels of:	Baseline	End of treatment	p
Total cholesterol (mg/dl)	211 ± 22	190 ± 26	≤ 0.05
HDL (mg/dl)	35 ± 8	37 ± 6	n.s.
LDL (mg/dl)	128 ± 21	127 ± 20	n.s.
Triglycerides (mg/dl)	186 ± 51	119 ± 38	≤ 0.05
Progesterone (ng/ml)	0.7 ± 0.3	0.6 ± 0.1	n.s.
Testosterone (ng/dl)	88 ± 38	57 ± 31	≤ 0.05
Free testosterone (ng/dl)	1.3 ± 0.5	0.6 ± 0.3	<  0.001
Androstenedione (ng/dl)	198 ± 59	165 ± 47	n.s.
17β-estradiol (ng/dl)	9.1 ± 3.7	9.2 ± 3.9	n.s.
Dehydroepiandrosterone sulfate (μg/dl)	530 ± 231	279 ± 87	<  0.01
SHBG (μg/dl)	2.6 ± 0.9	5.0 ± 2.1	<  0.001

Values are expressed as mean ± SD. p: value at end of treatment vs baseline

Instead, no significant changes were detected in the two MI-resistant women (data not shown)